Obesity, eating disorders

PubMed Free Full Text

Obesity: pharmacologic treatment

Australia

• Australian Family Physician
  • Pharmacotherapy for obesity [2017]

• Australian Journal of General Practice
  • New anti-obesity medications: Considerations and future directions in people with concurrent eating disorders [2023]

• Australian Prescriber
  • Medicines for long-term obesity management [2022]

Canada

• Canadian Agency for Drugs and Technologies in Health
  • Pharmacoeconomic Review Report: Naltrexone Hydrochloride and Bupropion Hydrochloride (Contrave) [2020]
  • Clinical Review Report: Naltrexone Hydrochloride and Bupropion Hydrochloride (Contrave) [2020]
  • CADTH Canadian Drug Expert Committee Recommendation: Naltrexone Hydrochloride and Bupropion Hydrochloride (Contrave — Bausch Health, Canada Inc.) [2020]

• Canadian Journal of Public Health
  • Drivers of medicalization in the Canadian Adult Obesity Clinical Practice Guidelines [2022]

• Obesity Canada
  • Pharmacotherapy in Obesity Management [2022]

Europe

• European Association for the Study of Obesity
  • 2014 EASO Position Statement on the Use of Anti-Obesity Drugs [2015]

• European Medicines Agency
  • Guideline on clinical evaluation of medicinal products used in weight management [2016]

Europe, United States

• Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
  • The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials [2023]

International

• BMC Medicine
  • Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review [2016]

• Current Obesity Reports
  • Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? [2021]

• Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
  • Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis [2022]

• Diabetology & Metabolic Syndrome
  • The best drug supplement for obesity treatment: a systematic review and network meta-analysis [2021]

• Frontiers in Endocrinology
  • The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta-regression analysis of randomized controlled trials [2023]

Republic of Korea

• Journal of Global Health
  • A nationwide pharmacovigilance investigation on trends and seriousness of adverse events induced by anti-obesity medication [2023]

Saudi Arabia

• Scientific World Journal
  • Safety Evaluation of Local Weight-Gain Formulas in the Saudi Arabian Markets [2015]

United Kingdom

• Advances in Therapy
  • Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom [2023]

• National Institute for Health and Care Excellence
  • Semaglutide for managing overweight and obesity [2023]
  • Liraglutide for managing overweight and obesity [2020]
  • Naltrexone–bupropion for managing overweight and obesity [2017]

United States

• American Gastroenterological Association
  • AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity [2022]

• Current Opinion in Endocrinology, Diabetes and Obesity
  • Pharmacotherapy in Pediatric Obesity: Current Evidence and Landscape [2021]

• Endocrine Practice
  • Anti-obesity Medication Use Among Adults with Overweight and Obesity in the United States: 2015–2018 [2021]

• Endocrine Society
  • Pharmacological management of obesity: an Endocrine Society clinical practice guideline [2015]

• Expert Opinion on Drug Safety
  • The risk of cardiovascular complications with current obesity drugs [2020]

• Expert Opinion on Pharmacotherapy
  • The limits and challenges of antiobesity pharmacotherapy [2020]
  • Anorectic state of obesity medications in the United States. Are leaner times ahead? [2020]

• JAMA Network Open
  • Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents [2023]

• Journal of Managed Care & Specialty Pharmacy
  • Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States [2022]

• Journal of Women's Health
  • Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists [2021]

• Obesity
  • Treatment of obesity: Pharmacotherapy trends in the United States from 1999 to 2010 [2015]

{Related topics}

• Topic
  • Obesity